首页> 外文期刊>BMC Veterinary Research >A neutralizing monoclonal antibody-based competitive ELISA for classical swine fever C-strain post–vaccination monitoring
【24h】

A neutralizing monoclonal antibody-based competitive ELISA for classical swine fever C-strain post–vaccination monitoring

机译:基于单克隆抗体的竞争性ELISA用于典型猪瘟C-菌株疫苗接近监测

获取原文
           

摘要

Virus neutralization test (VNT) is widely used for serological survey of classical swine fever (CSF) and efficacy evaluation of CSF vaccines. However, VNT is a time consuming procedure that requires cell culture and live virus manipulation. C-strain CSF vaccine is the most frequently used vaccine for CSF control and prevention. In this study, we presented a neutralizing monoclonal antibody (mAb) based competitive enzyme-linked immunosorbent assay (cELISA) with the emphasis on the replacement of VNT for C-strain post–vaccination monitoring. One monoclonal antibody (6B211) which has potent neutralizing activity against C-strain was generated. A novel cELISA was established and optimized based on the strategy that 6B211 can compete with C-strain induced neutralizing antibodies in pig serum to bind capture antigen C-strain E2. By testing C-strain VNT negative pig sera (n?=?445) and C-strain VNT positive pig sera (n?=?70), the 6B211 based cELISA showed 100% sensitivity (95% confidence interval: 94.87 to 100%) and 100% specificity (95% confidence interval: 100 to 100%). The C-strain antibody can be tested in pigs as early as 7?days post vaccination with the cELISA. By testing pig sera (n?=?139) in parallel, the cELISA showed excellent agreement (Kappa?=?0.957) with VNT. The inhibition rate of serum samples in the cELISA is highly correlated with their titers in VNT (r2?=?0.903, p??0.001). In addition, intra- and inter-assays of the cELISA exhibited acceptable repeatability with low coefficient of variations (CVs). This novel cELISA demonstrated excellent agreement and high level correlation with VNT. It is a reliable tool for sero-monitoring of C-strain vaccination campaign because it is a rapid, simple, safe and cost effective assay that can be used to monitor vaccination-induced immune response at the population level.
机译:病毒中和试验(VNT)广泛用于古典猪瘟(CSF)的血清学调查和CSF疫苗的功效评价。然而,VNT是需要细胞培养和实时病毒操纵的耗时程序。 C-菌株CSF疫苗是CSF控制和预防最常使用的疫苗。在该研究中,我们介绍了一种基于单克隆抗体(MAB)的竞争性酶联免疫吸附测定(Celisa),重点是替代VNT用于疫苗接种后的C-菌株。产生一种对C-菌株有效中和活性的一种单克隆抗体(6B211)。基于6B211可以与猪血清中的C-菌株诱导的中和抗体进行竞争以结合捕获抗原C-菌株E2的策略建立并优化了一种新的Celisa。通过测试C-菌株VNT阴性猪血清(N?=β445)和C-菌株VNT阳性猪血清(N?=Δ70),其6b211的Celisa显示出100%的灵敏度(95%置信区间:94.87至100% )和100%特异性(95%置信区间:100至100%)。 C-菌株抗体可以早在7.与胞质接种后7-粒子测试。通过并行地测试猪血清(N?= 139),Celisa与VNT显示出优秀的一致性(Kappa?= 0.957)。雌蕊中血清样品的抑制率与VNT中的滴度高(R2≤= 0.903,p≤0.001)。此外,Celisa的分析和分析和测定具有具有低变异系数(CVS)的可接受的可重复性。这部新颖的Celisa展示了与VNT的良好协议和高水平相关性。它是一种可靠的血清监测型C-应变疫苗接种运动的工具,因为它是一种快速,简单,安全和成本效益的测定,可用于监测人口水平的疫苗接种诱导的免疫应答。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号